Trial · NCT00944229
The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure
NCT00944229, Phase 3, Terminated, Columbia University; results first posted 2016-04-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure. Trials, record NCT00944229. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00944229
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure
- NCT number
- NCT00944229
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 58 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Heart Failure
- Interventions
- LOVAZA (Omega-3), Placebo
- First posted
- 2009-07-23
- Last updated
- 2016-05-25
- Results first posted
- 2016-04-22
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Peak VO2 | 0, 1 and 8 weeks of Omega 3 supplementation. | |
| Primary | Change in Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) After 8 Weeks of Omega 3 Supplementation. | 0 and after 8 weeks of Omega 3 supplementation. | |
| Primary | Change in Base Line Oxidized Low Density Lipoprotein (LDL) Level and in Response to Exercise | 0, 1 and 8 weeks of Omega 3 supplementation. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Peak VO2 | 0, 1 and 8 weeks of Omega 3 supplementation. | The principal investigator has left the institution. Attempts to contact the PI have been unsuccessful. Columbia will never have access to the data. Thus, data will not be analyzed. The only information available is the number of participants who started and completed the study, which was last reported to and approved by the IRB in March 2013. | ||
| PRIMARY | Change in Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) After 8 Weeks of Omega 3 Supplementation. | 0 and after 8 weeks of Omega 3 supplementation. | The principal investigator has left the institution. Attempts to contact the PI have been unsuccessful. Columbia will never have access to the data. Thus, data will not be analyzed. The only information available is the number of participants who started and completed the study, which was last reported to and approved by the IRB in March 2013. | ||
| PRIMARY | Change in Base Line Oxidized Low Density Lipoprotein (LDL) Level and in Response to Exercise | 0, 1 and 8 weeks of Omega 3 supplementation. | The principal investigator has left the institution. Attempts to contact the PI have been unsuccessful. Columbia will never have access to the data. Thus, data will not be analyzed. The only information available is the number of participants who started and completed the study, which was last reported to and approved by the IRB in March 2013. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | LOVAZA or Placebo | 58 | |
| Overall Study | COMPLETED | LOVAZA or Placebo | 33 | |
| Overall Study | NOT COMPLETED | LOVAZA or Placebo | 25 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | LOVAZA or Placebo | ||
| Total, other adverse events | LOVAZA or Placebo | 0 | 0 |
| Total, serious adverse events | LOVAZA or Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00944229
GET https://conductscience.org/api/trials/v1/NCT00944229/registered